Mr. Thomas Anyorigiya

Organisation: Navrongo Health Research Centre, Navrongo, Ghana

Position: Senior Research Officer

Thomas Anyorigiya is a senior research officer at the Navrongo Health Research Centre. He had his first degree, BSc (Chemistry) from the University of Science and Technology, Kumasi, Ghana, MSc (Pharmacology & Therapeutics) from the University of Ibadan, Nigeria and has recently submitted his PhD thesis (Clinical Pharmacology) at the University of Cape Town, South Africa. His doctoral research project was aimed at developing a feasible assay for the determination of amodiaquine and its active metabolite desethylamodiaquine and to describe the pharmacokinetics of amodiaquine/desethylamodiaquine in malaria patients in Ghana. Thomas has been involved in research at the Navrongo Health Research Centre in various capacities; first as a fieldworker/ field supervisor on the Vitamin A supplementation trial. He worked as a laboratory technician on the Navrongo Etaquine trial and was the laboratory manager at the Navrongo Health Research Centre until 2011. Thomas has been involved in several studies as an investigator, among which are:

i.        Home management of acute febrile illnesses in northern Ghana using artesunate–amodiaquine combination: The role of rapid malaria diagnostic testing

ii.      Mobile technology (MOTEC-PV) for safety monitoring of community-based integrated administration of ivermectin, praziquantel and albendazole for the control of schistosomiasis and lymphatic filariasis and intestinal helminthes in northern Ghana

iii.    INDEPTH Phase IV Effectiveness and Safety Studies (INESS)

iv.    A Phase 2/3 Randomized double-blind, Comparative Trial of Azithromycin plus Chloroquine versus Mefloquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Africa

v.      Phase 2/3, Open-Label, Comparative Trial of Azithromycin Plus Chloroquine versus Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children in Africa

His research interests are in chemotherapeutics,